Mizuho Medy Co Ltd
TSE:4595
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (7.2), the stock would be worth ¥1 163.11 (49% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 14.1 | ¥2 289 |
0%
|
| 3-Year Average | 7.2 | ¥1 163.11 |
-49%
|
| 5-Year Average | 6.7 | ¥1 088.55 |
-52%
|
| Industry Average | 24.8 | ¥4 034.18 |
+76%
|
| Country Average | 20.9 | ¥3 391.99 |
+48%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Mizuho Medy Co Ltd
TSE:4595
|
34.4B JPY | 14.1 | 10 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 64.1 | 58 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 22.2 | 26 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 31.3 | 37.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 23 | 22.8 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 26.2 | 24.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 33.1 | 43.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 21.1 | 18.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 43.7 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 22.3 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 17.2 | 21.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 20.9 |
| 70th Percentile | 32.2 |
| Max | 571 930 627.1 |
Other Multiples
Mizuho Medy Co Ltd
Glance View
Mizuho Medy Co., Ltd. engages in the research, development, manufacture and distribution of in-vitro diagnostic products. The company is headquartered in Tosu-Shi, Saga-Ken and currently employs 173 full-time employees. The company went IPO on 2015-12-17. The firm mainly provides in-vitro diagnostic pharmaceuticals, including immune serum test drugs, biochemical test drugs, urine and feces test drugs, microbial test drugs, blood test drugs, pathological test drugs and others, in hospital and medical practitioner fields. In addition, the Company also provides over-the-counter (OTC) drugs to pharmacies and drug stores, and sells fruit tree virus test drugs to which they apply the technology of immune serology test to agricultural test centers.
